(Q40092301)

17 September 2017

title

Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors (English)

1 reference

17 September 2017

1 reference

3

0 references

author name string

Hironobu Minami

1

1 reference

17 September 2017

Kenji Kawada

2

1 reference

17 September 2017

Koichi Kitagawa

4

1 reference

17 September 2017

Yon-il Kim

5

1 reference

17 September 2017

Kazuhiro Araki

6

1 reference

17 September 2017

Hirofumi Mukai

7

1 reference

17 September 2017

Makoto Tahara

8

1 reference

17 September 2017

Hikaru Nakajima

9

1 reference

17 September 2017

Keiko Nakajima

10

1 reference

17 September 2017

publication date

12 May 2008

1 reference

17 September 2017

1 reference

17 September 2017

volume

99

1 reference

17 September 2017

issue

7

1 reference

17 September 2017

page(s)

1492-1498

1 reference

The Ras-Raf-MEK-ERK pathway in the treatment of cancer

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00837.X

Targeting RAS signalling pathways in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00837.X

Cell signalling: growth factors and tyrosine kinase receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00837.X

BAY 43-9006: preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00837.X

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00837.X

Sorafenib: in advanced renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00837.X

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00837.X

Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00837.X

Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00837.X

Adrenomedullin and tumour angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00837.X

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00837.X

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00837.X

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00837.X

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00837.X

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00837.X

Sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00837.X

Bevacizumab in the treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00837.X

The safety of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00837.X

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00837.X

Drug insight: advances in renal cell carcinoma and the role of targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00837.X

10.1111/J.1349-7006.2008.00837.X

21 January 2018

Identifiers

DOI

1 reference

17 September 2017

1 reference